Zhitong Finance App News, Conoa-B (02162.HK) announced that the company's key research product CM512 (TSLP/IL-13 double antibody) has been included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration to treat chronic sinusitis with nasal polyps (CRSwnP).
智通財經·07/23/2026 04:09:03
語音播報
Zhitong Finance App News, Conoa-B (02162.HK) announced that the company's key research product CM512 (TSLP/IL-13 double antibody) has been included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration to treat chronic sinusitis with nasal polyps (CRSwnP).